These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19783793)

  • 1. Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.
    Moreira JM; Ohlsson G; Gromov P; Simon R; Sauter G; Celis JE; Gromova I
    Mol Cell Proteomics; 2010 Jan; 9(1):161-77. PubMed ID: 19783793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas.
    Ohlsson G; Moreira JM; Gromov P; Sauter G; Celis JE
    Mol Cell Proteomics; 2005 Apr; 4(4):570-81. PubMed ID: 15734831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoexpression analysis and prognostic value of BLCAP in breast cancer.
    Gromova I; Gromov P; Kroman N; Wielenga VT; Simon R; Sauter G; Moreira JM
    PLoS One; 2012; 7(9):e45967. PubMed ID: 23049907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology.
    Lee H; Kim K; Woo J; Park J; Kim H; Lee KE; Kim H; Kim Y; Moon KC; Kim JY; Park IA; Shim BB; Moon JH; Han D; Ryu HS
    Mol Cell Proteomics; 2018 Sep; 17(9):1788-1802. PubMed ID: 29950347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer.
    Gromova I; Svensson S; Gromov P; Moreira JMA
    PLoS One; 2017; 12(11):e0188827. PubMed ID: 29190807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas.
    Celis JE; Ostergaard M; Basse B; Celis A; Lauridsen JB; Ratz GP; Andersen I; Hein B; Wolf H; Orntoft TF; Rasmussen HH
    Cancer Res; 1996 Oct; 56(20):4782-90. PubMed ID: 8840999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression.
    Kawaguchi M; Hara N; Bilim V; Koike H; Suzuki M; Kim TS; Gao N; Dong Y; Zhang S; Fujinawa Y; Yamamoto O; Ito H; Tomita Y; Naruse Y; Sakamaki A; Ishii Y; Tsuneyama K; Inoue M; Itoh J; Yasuda M; Sakata N; Jung CG; Kanazawa S; Akatsu H; Minato H; Nojima T; Asai K; Miura Y
    BMC Cancer; 2016 Oct; 16(1):805. PubMed ID: 27756245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis.
    Barboro P; Rubagotti A; Orecchia P; Spina B; Truini M; Repaci E; Carmignani G; Romagnoli A; Introini C; Boccardo F; Carnemolla B; Balbi C
    Cell Oncol; 2008; 30(1):13-26. PubMed ID: 18219107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomics analysis of bladder cancer exosomes.
    Welton JL; Khanna S; Giles PJ; Brennan P; Brewis IA; Staffurth J; Mason MD; Clayton A
    Mol Cell Proteomics; 2010 Jun; 9(6):1324-38. PubMed ID: 20224111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder.
    Keymoosi H; Gheytanchi E; Asgari M; Shariftabrizi A; Madjd Z
    Asian Pac J Cancer Prev; 2014; 15(5):2013-20. PubMed ID: 24716927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.
    Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
    Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor.
    Chiang CY; Pan CC; Chang HY; Lai MD; Tzai TS; Tsai YS; Ling P; Liu HS; Lee BF; Cheng HL; Ho CL; Chen SH; Chow NH
    Clin Cancer Res; 2015 Dec; 21(24):5601-11. PubMed ID: 26286913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival.
    Luo JH; Xie D; Liu MZ; Chen W; Liu YD; Wu GQ; Kung HF; Zeng YX; Guan XY
    Int J Cancer; 2008 Jun; 122(11):2554-61. PubMed ID: 18246597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer.
    Chen CL; Chung T; Wu CC; Ng KF; Yu JS; Tsai CH; Chang YS; Liang Y; Tsui KH; Chen YT
    Mol Cell Proteomics; 2015 Sep; 14(9):2466-78. PubMed ID: 26081836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of CD24: association with invasiveness in urothelial carcinoma of the bladder.
    Choi YL; Lee SH; Kwon GY; Park CK; Han JJ; Choi JS; Choi HY; Kim SH; Shin YK
    Arch Pathol Lab Med; 2007 Feb; 131(2):275-81. PubMed ID: 17284113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.
    Sitnikova L; Mendese G; Liu Q; Woda BA; Lu D; Dresser K; Mohanty S; Rock KL; Jiang Z
    Clin Cancer Res; 2008 Mar; 14(6):1701-6. PubMed ID: 18347170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beclin 1 and bcl-2 expressions in bladder urothelial tumors and their association with clinicopathological parameters.
    Baspinar S; Bircan S; Yavuz G; Kapucuoglu N
    Pathol Res Pract; 2013 Jul; 209(7):418-23. PubMed ID: 23722017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3 expression is associated with bladder cancer progression and clinical outcome.
    Canesin G; Gonzalez-Peramato P; Palou J; Urrutia M; Cordón-Cardo C; Sánchez-Carbayo M
    Tumour Biol; 2010 Aug; 31(4):277-85. PubMed ID: 20401558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder Cancer.
    Witzke KE; Großerueschkamp F; Jütte H; Horn M; Roghmann F; von Landenberg N; Bracht T; Kallenbach-Thieltges A; Käfferlein H; Brüning T; Schork K; Eisenacher M; Marcus K; Noldus J; Tannapfel A; Sitek B; Gerwert K
    Am J Pathol; 2019 Mar; 189(3):619-631. PubMed ID: 30770125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel strategy based on histological protein profiling in-silico for identifying potential biomarkers in urinary bladder cancer.
    Segersten MU; Edlund EK; Micke P; de la Torre M; Hamberg H; Edvinsson AE; Andersson SE; Malmström PU; Wester HK
    BJU Int; 2009 Dec; 104(11):1780-5. PubMed ID: 19522865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.